FDA authorizes use of first device to treat patients with dialysis-related amyloidosis

The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA).

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436864.htm

Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news

More News: American Health | Amyloidosis | Dialysis | Food and Drug Administration (FDA)